Pfizer and BioNTech have begun a rolling submission of their vaccine candidate to the European Medicines Agency (EMA). AstraZeneca has also begun a rolling review process. The rolling submission allows regulators to evaluate data as it becomes available, which can decrease the time it takes to decide on an approval once the final submission is made. Each cycle of the EMA’s rolling review typically takes two weeks and the duration of the review of the final application will depend on how much data was evaluated during the rolling process.
anonymousCoronavirus October 07, 2020 at 10:18 am00